Global Cancer Diagnostics Market to Reach US$153 Billion by 2032, Driven by Precision Medicine, Early Detection, and AI-Enabled Imaging
Industry Experts, Inc. has published the new market research report "Global Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities." The study estimates the worldwide cancer diagnostics market at US$95.3 billion in 2025, projected to expand to US$153 billion by 2032, growing at a CAGR of 7% during 2025–2032. Growth is underpinned by rising global cancer incidence, government screening initiatives, increasing adoption of precision medicine, and technological advancements such as liquid biopsy, next-generation sequencing, and AI-powered imaging platforms that enhance diagnostic accuracy and efficiency.
The report highlights North America as the largest regional market, commanding 39.8% share in 2025, supported by robust healthcare infrastructure, advanced R&D ecosystems, favourable reimbursement policies, and strong adoption of innovative diagnostic modalities. The U.S. dominates within the region due to high screening rates and established cancer research networks. In contrast, the Asia-Pacific region is the fastest-growing, anticipated to register a CAGR of 7.9% during 2025–2032. Rising cancer incidence, a rapidly aging population, expanding healthcare access, and government-backed screening programs are accelerating demand in China, India, and Japan, making the region a strategic growth hub.

By cancer diagnostics technology, in vitro diagnostics (IVD) leads in 2025, benefiting from the increasing use of PCR, NGS, immunoassays, and liquid biopsy for early cancer detection. Meanwhile, Laboratory-Developed Tests (LDTs) are projected to grow the fastest, at 9% CAGR, owing to their critical role in precision oncology and targeted therapy guidance. By application, breast cancer diagnostics remain the largest segment in 2025, reflecting high prevalence and government-backed screening programs. Colorectal cancer diagnostics will expand the quickest, at 8.3% CAGR, driven by rising incidence, broader screening access, and adoption of non-invasive DNA- and AI-based tests. Among end-use facilities, hospitals dominate with 49% share in 2025, while diagnostic laboratories are projected to see strong growth at 7.6% CAGR, supported by cost efficiency and high-volume test capacity.
The report segments the global cancer diagnostics market by technology (IVD, diagnostic imaging, tumor biomarker tests, biopsy techniques, LDTs, and emerging technologies), application (breast, lung, colorectal, prostate, liver, blood, kidney, pancreatic, ovarian, melanoma, and others), and end user (hospitals, diagnostic laboratories, academic & research institutes, and others). Geographic coverage spans five major regions with detailed analysis of over 14 independent countries. The study profiles more than 15 leading companies, including Abbott Laboratories, Agilent Technologies, Becton Dickinson, bioMerieux, Bio-Rad, Danaher, F. Hoffmann-La Roche, GE Healthcare, Hologic, Illumina, Philips, Myriad Genetics, QIAGEN, Siemens Healthineers, and Thermo Fisher Scientific.
For sample pages or purchase options, contact +1-320-497-3787 or visit Cancer Diagnostics Market Report.
About Industry Experts, Inc.
Industry Experts, Inc., ranks among the leading market research providers globally. The company's off-the-shelf and customized business intelligence reports offer strategic insights and valuable guidance to enable various stakeholders - corporate strategists, analysts, researchers, and startups, among others - in obtaining unbiased current and future market data. For more information, contact us on +1-320-497-3787 or visit https://industry-experts.com.
Comments
Post a Comment